

# PREHOSPITAL and DISASTER MEDICINE

Médecine Pré-Hospitalière et Médecine de Catastrophe

Medicina Prehospitalaria y de Catástrofes

病院にかかる前の処置と  
災害医療

Volume 15, Number 3

July–September 2000

## Special Report

KAMEDO Report Summaries

## Original Research

Medical Evacuation Programme for the 1999 Crisis in Kosovo

## Brief Report

Bogus Doctors during Multi-Casualty Events and Disasters

## Abstracts of Scientific Papers

Fifth Asia-Pacific Conference on  
Disaster Medicine

Vancouver, British Columbia, CANADA

28 — 30 September, 2000

## Continuing Education

Fredrick C. Cuny Memorial Series

Group Dynamics in Disasters

## Forum

Disasters and Therapeutic or Prophylactic Interventions

The Official Journal of the  
World Association for Disaster and Emergency Medicine  
and the

Nordic Society of Disaster Medicine

# To the Rescue



**NEW**  
**ZOLL** M Series  
Defibrillator Monitor Pacemaker

**Smaller. Lighter.  
Brighter. And  
Really Tough.**

Life on the road is rough. You need a defibrillator that can handle it. Lightweight. Fast and ready. You need the M Series. Eleven pounds of power. Packaged to meet rigorous military design standards. With an FED display that is unmatched. View it from any angle. In any light. Anywhere. The M Series Defibrillator Monitor Pacemaker. New from ZOLL. Take it on the road.

**Call 800-348-9011  
or visit [www.zoll.com](http://www.zoll.com)**

**ZOLL**  
*It's about time.*

© 1998 ZOLL Medical Corporation, Burlington, MA 01803



Acute  
Myocardial Infarction

American Heart  
Association<sup>SM</sup>  
Fighting Heart Disease  
and Stroke



Revised for 2000

# ADVANCED CARDIAC LIFE SUPPORT



# Now on the ACLS guidelines

**Cordarone I.V. is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.**

Cordarone I.V. is contraindicated in patients with cardiogenic shock, marked sinus bradycardia, and second- or third-degree AV block in the absence of a functioning pacemaker. Hypotension is the most common adverse effect seen with Cordarone I.V. and may be related to the rate of infusion. The most important treatment-emergent adverse effects are hypotension (16%), bradycardia (4.9%), liver function test abnormalities (3.4%), cardiac arrest (2.9%), VT (2.4%), congestive heart failure (2.1%), cardiogenic shock (1.3%), and AV block (0.5%).

**Please see adjacent brief summary of Prescribing Information.**

# Cordarone<sup>®</sup>

(amiodarone HCl)



150 mg/3 mL

**CORDARONE I.V.** - Brief summary of prescribing information

**SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION**

**INDICATIONS AND USAGE:** Cordarone I.V. is indicated for 1) initiation of treatment and prophylaxis of frequently recurring VF and hemodynamically unstable VT in patients refractory to other therapy; 2) treatment of VT/VF in patients for whom oral Cordarone is indicated, but who are unable to take oral medication.

**CONTRAINDICATIONS:** In patients with: 1) known hypersensitivity to any of its components; 2) cardiogenic shock; 3) marked sinus bradycardia; 4) 2nd- or 3rd-degree AV block unless a functioning pacemaker is available.

**WARNINGS: Hypotension:** Hypotension was the most common adverse effect seen with Cordarone I.V. in clinical trials (288 of 1836 patients; 16%). Clinically significant hypotension was most often seen in the first several hours of treatment and was not dose related, but appeared to be related to rate of infusion. Hypotension necessitating alterations in therapy was reported in 3% of patients, with permanent discontinuation required in < 2%. Treat hypotension initially by slowing the infusion; additional standard therapy may be needed including vasopressor drugs, positive inotropic agents, and volume expansion. **The initial rate of infusion should be monitored closely and should not exceed that prescribed in DOSAGE AND ADMINISTRATION** (see full prescribing information).

**Bradycardia and AV Block:** Drug-related bradycardia occurred in 90 (4.9%) of 1836 patients receiving Cordarone I.V. in clinical trials; it was not dose related. Treat bradycardia by slowing the infusion rate or discontinuing Cordarone I.V. In some patients, a pacemaker is required. Despite such measures, bradycardia was progressive and terminal in 1 patient during controlled trials. Treat patients with a known predisposition to bradycardia or AV block with Cordarone I.V. in a setting where a temporary pacemaker is available.

**Long-term Use:** See labeling for oral Cordarone. Experience is limited in patients receiving Cordarone I.V. for > 3 weeks.

**Neonatal Hypo- or Hyperthyroidism:** Although oral Cordarone use during pregnancy is uncommon, there have been a small number of published reports of congenital goiter/hypothyroidism and hyperthyroidism. If Cordarone I.V. is given during pregnancy, apprise the patient of the potential hazard to the fetus (see full prescribing information).

**PRECAUTIONS:** Cordarone I.V. should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, are thoroughly familiar with the risks and benefits of Cordarone, and have access to facilities adequate for monitoring the effectiveness and side effects of treatment.

**Liver Enzyme Elevations:** Elevations of blood hepatic enzyme values—ALT, AST, and GGT—are seen commonly in patients with immediately life-threatening VT/VF. Interpreting elevated AST activity can be difficult because values may be elevated in patients who have had recent myocardial infarction, CHF, or multiple electrical defibrillations. In clinical studies, approximately 54% of patients had baseline liver enzyme elevations; 13% had clinically significant elevations. Liver enzyme elevations may improve during therapy or remain at baseline levels. Baseline abnormalities in hepatic enzymes are not a contraindication to treatment.

Two cases of fatal hepatocellular necrosis have been reported after Cordarone I.V. treatment of atrial arrhythmias with an initial infusion rate of 1500 mg over 5 hours, a rate much higher than recommended. Both patients developed hepatic and renal failure within 24 hours after the start of Cordarone I.V. and died on day 14 and 4, respectively. Because these episodes of hepatic necrosis may have been due to rapid infusion rate with possible rate-related hypotension, **the initial rate of infusion should be monitored closely and should not exceed that prescribed in DOSAGE AND ADMINISTRATION** (see full prescribing information).

In patients with life-threatening arrhythmias, weigh the potential risk of hepatic injury against the potential benefit of Cordarone I.V., but carefully monitor patients for evidence of progressive hepatic injury. Give consideration to reducing administration rate or withdrawing Cordarone I.V. in such cases.

**Proarrhythmia:** Like all antiarrhythmics, Cordarone I.V. may cause a worsening of existing arrhythmias or precipitate a new arrhythmia. Proarrhythmia, primarily torsades de pointes, has been associated with prolongation by Cordarone I.V. of the QTc interval to  $\geq 500$  ms. Although QTc prolongation occurred frequently in Cordarone I.V. patients, torsades de pointes or new-onset VF occurred infrequently (< 2%). Monitor patients for QTc prolongation during Cordarone I.V. infusion.

**Pulmonary Disorders: ARDS:** Two percent of patients were reported to have adult respiratory distress syndrome (ARDS) during clinical studies. ARDS can arise after a variety of lung injuries, such as those resulting from trauma, shock, prolonged cardiopulmonary resuscitation, and aspiration pneumonia, conditions present in many of the patients enrolled in the clinical studies. It is not possible to determine what role, if any, Cordarone I.V. played in causing or exacerbating the pulmonary disorder in those patients.

Postoperatively, ARDS has been reported in patients receiving oral Cordarone who have undergone either cardiac or noncardiac surgery. Although patients usually respond well to vigorous respiratory therapy, in rare instances the outcome has been fatal. Until further studies are performed,  $\text{FiO}_2$  and the determinants of oxygen delivery to the tissues (e.g.,  $\text{SaO}_2$ ,  $\text{PaO}_2$ ) should be closely monitored in Cordarone patients.

**Pulmonary fibrosis:** Only 1 of more than 1000 patients treated with Cordarone I.V. in clinical studies developed pulmonary fibrosis. In that patient, the condition was diagnosed 3 months after Cordarone I.V. treatment, during which time she received oral Cordarone. Pulmonary toxicity is a well-recognized complication of long-term Cordarone use (see labeling for oral Cordarone).

**Surgery:** Close perioperative monitoring is recommended in amiodarone-treated patients undergoing general anesthesia as they may be more sensitive to the myocardial depressant and conduction effects of halogenated inhalational anesthetics.

**Drug Interactions:** Amiodarone can inhibit metabolism mediated by cytochrome P-450 enzymes, probably accounting for the significant effects of oral Cordarone (and presumably Cordarone I.V.) on the pharmacokinetics of various therapeutic agents including digoxin, quinidine, procainamide, warfarin, dextromethorphan, and cyclosporine. Hemodynamic and electrophysiologic interactions also have been observed after concomitant propranolol, diltiazem, and verapamil therapy. Agents producing a significant effect on amiodarone pharmacokinetics include phenytoin, cimetidine, and cholestyramine. Because of the long half-life of amiodarone, drug interactions may persist long after its discontinuation. Few data are available on drug interactions with Cordarone I.V.

Except as noted, the following summarizes important interactions between oral Cordarone and other therapeutic agents. **Drugs Whose Effects May Be Increased (inc.) By Cordarone:** Warfarin (prothrombin time inc.), Digoxin (serum concentration inc.), Quinidine (serum concentration inc.), Procainamide (serum concentration, NAPA concentration inc.), Disopyramide (QT prolongation inc., which could cause arrhythmia), Fentanyl (may cause hypotension, bradycardia, decreased cardiac output), Flecainide (reduces the flecainide dose needed to maintain therapeutic plasma concentrations), Lidocaine (Oral: sinus bradycardia in 1 patient during local anesthesia; I.V.: seizure associated with inc. lidocaine concentration observed in 1 patient), Cyclosporine (produces persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in cyclosporine dose). **Drugs That May Interfere With The Actions Of Cordarone:** Cholestyramine (enterohepatic elimination of amiodarone inc.; may reduce serum levels and half-life), Cimetidine (serum amiodarone levels inc.), Phenytoin (decreases serum amiodarone levels).

**Potential drug class interactions with Cordarone:** Beta Blockers: Since Cordarone has weak beta-blocking activity, use with beta-blocking agents could increase risk of hypotension and bradycardia. Calcium Channel Blockers: Cordarone inhibits AV conduction and decreases myocardial contractility, increasing the risk of AV block with verapamil or diltiazem or of hypotension with any calcium channel blocker. Volatile Anesthetic Agents: (see PRECAUTIONS, Surgery). In addition to the interactions above, chronic (> 2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.

**Electrolyte Disturbances:** Correct cases of hypokalemia or hypomagnesemia whenever possible before treating with Cordarone I.V., as these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsades de pointes. Give special attention to electrolyte and acid-base balance in patients with severe or prolonged diarrhea or receiving concomitant diuretics.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** No carcinogenicity studies were conducted with Cordarone I.V. However, oral Cordarone caused a statistically significant, dose-related increase in the incidence of thyroid tumors (follicular adenoma and/or carcinoma) in rats. The incidence of thyroid tumors in rats was greater than the incidence in controls even at the lowest dose tested, i.e., 5 mg/kg/day (approx. 0.08 times the maximum recommended human maintenance dose). Mutagenicity studies conducted with amiodarone HCl were negative.

No fertility studies were conducted with Cordarone I.V. (see full prescribing information).

\*600 mg in a 50 kg patient (dose compared on a body surface area basis)

**Pregnancy: Category D.** See WARNINGS, Neonatal Hypo- or Hyperthyroidism. In addition to infrequent congenital goiter/hypothyroidism and hyperthyroidism, amiodarone has caused a variety of adverse effects in animals (see full prescribing information). In a

reproductive study in which amiodarone was given intravenously to rabbits at dosages about 0.1, 0.3, and 0.7 times the maximum recommended human dose (MRHD) on a body surface area basis, maternal deaths occurred in all groups, including controls. Embryotoxicity occurred at dosages of 0.3 x MRHD and above. No evidence of embryotoxicity was observed at 0.1 x MRHD and no teratogenicity was observed at any dosages. In a teratology study in which amiodarone was administered by continuous iv. infusion to rats at dosages about 0.4, 0.7, and 1.4 times the MRHD



# Cordarone® (amiodarone HCl)

150 mg/3 mL

when compared on a body surface area basis, maternal toxicity and embryotoxicity were observed in the 1.4 x MRHD group. Cordarone I.V. should be used during pregnancy only if the potential benefit to the mother justifies the risk to the fetus.

**Nursing Mothers:** Amiodarone is excreted in human milk; breast-feeding could expose the nursing infant to a significant dose of drug. Nursing offspring of lactating rats administered amiodarone demonstrated reduced viability and reduced body weight gains. Weigh the risk of exposing the infant to amiodarone against the potential benefit of arrhythmia suppression in the mother. Advise the mother to discontinue nursing.

**Labor and Delivery:** It is not known whether use of Cordarone during labor or delivery has any immediate or delayed adverse effects. Preclinical studies in rodents have not shown any effect on duration of gestation or parturition.

**Pediatric Usage:** Safety and efficacy of Cordarone in the pediatric population have not been established; such use is not recommended.

**ADVERSE REACTIONS:** In a total of 1836 patients in clinical trials, 14% received Cordarone I.V. for  $\geq 1$  week, 5% received it for  $\geq 2$  weeks, 2% received it for 3 weeks, and 1% received it for > 3 weeks, without an increased incidence of severe adverse reactions. The mean duration of therapy was 5.6 days; median exposure was 3.7 days. The most important treatment-emergent adverse effects were hypotension, asystole/cardiac arrest/EMD, cardiogenic shock, CHF, bradycardia, LFT abnormalities, VT, and AV block. Treatment was discontinued for about 9% of patients because of adverse effects, most commonly hypotension (1.6%), asystole/cardiac arrest/EMD (1.2%), VT (1.1%), and cardiogenic shock (1%).

The following are the most common (incidence  $\geq 2\%$ ) and possibly drug-related adverse events during Cordarone I.V. clinical trials involving 1836 patients with life-threatening VT/VF. Data from all assigned treatment groups are pooled because none of the adverse events appeared to be dose-related: Fever, 2.0%; Bradycardia, 4.9%; CHF, 2.1%; Heart arrest, 2.9%; Hypotension, 15.6%; VT, 2.4%; LFTs abnormal, 3.4%; Nausea, 3.9%. Other possibly drug-related adverse events reported in < 2% of patients receiving Cordarone I.V. in clinical studies included abnormal kidney function, atrial fibrillation, diarrhea, inc. ALT, inc. AST, lung edema, nodal arrhythmia, prolonged QT interval, respiratory disorder, shock, sinus bradycardia, Stevens-Johnson syndrome, thrombocytopenia, VF, and vomiting. In postmarketing surveillance, toxic epidermal necrolysis, pancytopenia, neutropenia, angioedema, and anaphylactic shock also have been reported.

This Brief Summary text is based on Direction Circular CI 5032-3, Revised 5/7/99.

# Table of Contents

---

Editor's Corner	
<b>Where Are We?</b> .....	7
<i>Marvin L. Birnbaum, MD, PhD</i>	
Special Report	
<b>KAMEDO Report Summaries</b> .....	13
Original Research	
<b>Field Epidemiology Assessment for a Medical Evacuation Programme Related to the Crisis in Kosovo, 1999</b> .....	19
<i>Douglas W. MacPherson, MD, MSc(CTM), FRCPC; Fausto Mariani, MD; Jacqueline Weekers, MPH; Brian D. Gushulak, MD</i>	
Brief Report	
<b>Bogus Doctor Deceptions during Multi-Casualty Events and Disasters</b> .....	25
<i>Dr. Antony Nocera, FACEM; Ms. Anne M. Newton, B. Nursing, Dip. App. Sci.</i>	
Continuing Education	
<i>Fredrick C. Cuny Memorial Series</i>	
<b>Principles of Disaster Management</b>	
<b>Lessons 9: Group Dynamics in Disasters</b> .....	28
<i>Fred C. Cuny</i>	
Fifth Asia-Pacific Conference on Disaster Medicine	
<b>Abstracts for the Fifth Asia-Pacific Conference on Disaster Medicine Supplement 2</b> .....	S19
<b>Spanish Abstract Translations</b> .....	9
<b>Guidelines for Authors</b> .....	11
<b>Guidelines for Advertisers</b> .....	12
<b>Calendar</b> .....	37
<b>Forum</b> .....	34

**Editorial Office**

University of Wisconsin-Madison USA  
Marvin L. Birnbaum, MD, PhD, Editor-in-Chief

**Associate Editor**  
Colleen Heinkel

**Production Editor**  
Donna Schaan

**Web Production Editor**  
Megan Phillips

**Advertising**  
Mary Duss

**Subscriptions**  
Colleen Heinkel

**Editorial Office**  
University of Wisconsin-Madison

**Publisher**  
World Association for Disaster and  
Emergency Medicine  
Madison, Wisconsin USA

*Prehospital and Disaster Medicine* (ISSN 1049-023X) is published quarterly in the months of January, April, July, and October by the World Association for Disaster and Emergency Medicine. *Prehospital and Disaster Medicine* incorporates the *Journal of the World Association for Emergency and Disaster Medicine* and the *Journal of Prehospital Medicine*.

**Editorial Information:** Submit manuscripts and editorial inquiries to: Marvin L. Birnbaum, PhD, MD, Editor, *Prehospital and Disaster Medicine*, Clinical Science Center, 600 N. Highland (E5/615), Madison, WI 53792, USA; Telephone/Facsimile (01) (608) 263-9641; E-mail: mlb@medicine.wisc.edu

**Subscription Information:** One year (four issues)—Institutions: (U.S.) \$78; Individuals: \$55; Canadian and international subscribers must add \$15 per year for postage. Claims of non-receipt or damaged issues must be filed within three months of cover date. POSTMASTER: Send address changes to *Prehospital and Disaster Medicine*, 1930 Monroe Street, Suite 304, Madison, WI 53711 USA.


**Advertising Information:** Mary Duss; *Prehospital and Disaster Medicine*, Clinical Science Center, 600 N. Highland (E5/615), Madison, WI 53792 USA

**Abstracts:** Comprehensively abstracted by the National Library of Medicine (Medline), Cumulative Index to Nursing and Allied Health (CINAHL) and Health Star Cumulative Index. The database is available online via BRS, Data-Star, and DIALOG, and on CD-ROM through CD Plus, Compact Cambridge and Silver Platter. Abstracts and search capability available on the Internet at: <http://pdm.medicine.wisc.edu>.

Copyright © 2000 by the World Association for Disaster and Emergency Medicine. Periodicals postage paid at Madison, WI and at additional mailing offices

Bulk Rate U.S. Postage PAID Conrath, PA Permit No. 1708
--

Standard Mail Enclosed




**12<sup>th</sup> World Congress  
on  
Disaster and Emergency Medicine**

**WADEM**

**World Association for Disaster and Emergency Medicine**

**May 9 – 12, 2001  
LYON, FRANCE**



## EDITOR-IN-CHIEF

**Marvin L. Birnbaum, MD,  
PhD**

University of Wisconsin–Madison  
Madison, Wisconsin USA

## ASSOCIATE EDITORS

**Wolfgang Dick, Dr Med**

Johannes Gutenberg Universität  
Mainz, Germany

**Kimball Maull, MD**

Carraway Injury Control Institute  
Birmingham, Alabama USA

**Ernesto A. Pretto, MD**

University of Pittsburgh  
Pittsburgh, Pennsylvania USA

**Steven Rottman, MD**

University of California–  
Los Angeles  
Los Angeles, California USA

## SECTION EDITORS

**Terrorism**

**Michael Moles, MD**

Prince Philip Hospital  
Hong Kong University  
Hong Kong

## PAST EDITORS

**R Adams Cowley, MD**

Deceased  
(JWAEDM 1986–1987)

**Peter Safar, MD**

Safar Center  
University of Pittsburgh  
Pittsburgh, Pennsylvania USA  
(JWAEDM 1981–1985)

**Michael Gunderson, REMT-P**

Institute for Prehospital  
Medicine  
Tempe, Arizona USA

## CONSULTING EDITORS

**S. William A. Gunn, MD**

European Centre for Disaster  
Medicine  
Geneva, Switzerland

**Peter Safar, MD**

Safar Center  
University of Pittsburgh  
Pittsburgh, Pennsylvania USA

**Martin Silverstein, MD**

Uniformed Services University  
of the Health Sciences  
Bethesda, Maryland USA

**Ronald Stewart, MD**

Victoria Hospital  
Halifax, Nova Scotia Canada

## EDITORIAL BOARD

**Jakov Adler, MD**

Jerusalem, Israel

**Ahmed Ammar, MD**

Cairo, Egypt

**V. Anantharaman, MD**

Singapore General Hospital  
Singapore

**Paul B. Anderson**

Lincoln Medical Education  
Foundation  
Rural EMS Institute  
Lincoln, Nebraska USA

**Bishara Atiyeh, MD**

American University  
Beirut, Lebanon

**Jack Ayres, JD, REMT-P**

University of Texas Health  
Science Center  
Dallas, Texas USA

**Jan Babik, MD**

Kosice Burn Center  
Kosice-Saca, Slovakia

**Peter Baskett, MD**

Frenchay Hospital  
Bristol, UK

**Richard A. Bissell, PhD**

University of Maryland–  
Baltimore Campus  
Baltimore, Maryland USA

**Fredrick M. Burkle, MD,  
MPH**

John A. Burns School of  
Medicine and School of  
Public Health  
University of Hawaii  
Honolulu, Hawaii USA

**Jeff Clawson, MD**

Medical Priority Consultants,  
Inc.  
Salt Lake City, Utah USA

**Felipe Cruz-Vega, MD**

Social Security  
Mexico City, Mexico

**Richard O. Cummins, MD**

University of Washington  
Seattle, Washington USA

**Craig DeAtley, PA-C**

George Washington University  
Medical Center  
Washington, D.C. USA

**Claude de Ville de Goyet, MD**

Pan-American Health  
Organization/World Health  
Organization

**James DuCharme, MD**

Royal Victoria Hospital  
Montréal, Québec Canada

**Judith Fisher, MD**

British Association for  
Immediate Care  
London, UK

**Malcolm Fisher, MD**

Royal North Shore Hospital  
Sydney, Australia

**Alain Flaujat, MD**

Editor, *Ameliasp*  
Olonzaio, France

**Erik S. Gaul**

TriData Corporation  
Arlington, Virginia USA

**Sergey Goncharov, MD**

All-Russian Disaster Medicine  
Center  
Moscow, Russia

**Michael Gunderson, REMT-P**

Institute for Prehospital  
Medicine  
Tempe, Arizona USA

**Borje Hallen, MD**

Karolinska Sjukhuset  
Stockholm, Sweden

**Connie A. Jastremski, RN,  
MS**

Syracuse, New York USA

**Mark S. Johnson**

Alaska Department of Public  
Health  
Juneau, Alaska USA

**Mark Keim, MD**

Center for Disease Control and  
Prevention  
Atlanta, Georgia, USA

**Mark Klyachko, PhD**

Center on Earthquake  
Engineering  
Petropavlovsk, Kam, Russia

**Radana Konigova, MD**

Charles University  
Prague, Czech Republic

**Per Kulling, MD**

Swedish Poison Information  
Centre  
Stockholm, Sweden

**John C. Lane, MD**

University of Campinas  
Medical Center  
Sao Paulo, Brazil

**Baxter Larmon, PhD,  
EMT-P**

University of California–  
Los Angeles Medical Center  
Los Angeles, California USA

**Todd J. LeDuc**

Broward County Commission  
Ft. Lauderdale, Florida USA

**Prof. Li Zhong-Hao, MD**

Beijing Emergency Medical  
Center  
Beijing, China

**Susan D. McHenry**

National Highway Traffic  
Safety Administration  
Washington, D.C. USA

**Sergio Magalini, MD**

Università Cattolica del Sacro  
Cuore  
Rome, Italy

**Michele Masellis, MD**

Osp. Reg. Civico  
Palermo, Italy

**Eric Noji, MD**

Center for Disease Control and  
Prevention  
Atlanta, Georgia, USA

**Karl-Axel Norberg, MD, PhD**

Stockholm, Sweden

**Judy Olson, BSN, MEd**

University of Wisconsin–Madison  
Madison, Wisconsin USA

**Muneo Ohta, MD**

Senri Medical Center  
Osaka, Japan

**Paul Paris, MD**

Center for Emergency  
Medicine  
University of Pittsburgh  
Pittsburgh, Pennsylvania  
USA

**Georg Petroianu, MD**

University of Heidelberg  
Mannheim, Germany

**Hugo Prado, MD**

Pan-American Health  
Organization/World Health  
Organization

**R Abdul Radjak, MD**

Ministry of Health  
Jakarta, Indonesia

**Daniel Rodriguez, MD**

San Jose, Costa Rica

**Leonid B. Roshal, MD**

Institute of Pediatrics  
Academy of Medical Sciences  
Moscow, Russia

**Don Schramm**

Disaster Management Center  
University of Wisconsin  
Madison, Wisconsin USA

**Knut Ole Sundnes, MD**

Baerum Hospital  
Oslo, Norway

**Frank Thomas, MD**

Latter Day Saints Hospital  
Salt Lake City, Utah USA

**Shao Xiaohong, MD**

Peking Union Medical College  
Chinese Academy of Medical  
Science  
Beijing, China

**Samuel Stratton, MD**

Los Angeles County  
Los Angeles, California USA

**Takashi Ukai, MD**

Osaka City General Hospital  
Osaka, Japan

**Yasuhiro Yamamoto, MD**

Department of Emergency and  
Critical Medicine  
Tokyo, Japan

**Harsh Wardham, MD**

Sundar Lal Jain Hospital  
Delhi, India